Previous 10 | Next 10 |
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...
PDS Biotechnology (NASDAQ:PDSB) is scheduled to announce FY earnings results on Wednesday, March 23rd, before market open. The consensus EPS Estimate is -$0.25 (+71.9% Y/Y) For further details see: PDS Biotechnology FY 2021 Earnings Preview
Phase 2 Enrollment Is On Schedule. PDS Biotechnology has announced that the National Cancer Institute (NCI) Phase 2 trial testing PDS0101 in a triple-therapy regimen has reached the target patient enrollment in one of its two treatment arms. This trial is testing PDS0101 in combination with tw...
Clinical-stage immunotherapy company, PDS Biotechnology (NASDAQ:PDSB), announced on Tuesday the achievement of a key enrollment target in Phase 2 clinical trial for a combination therapy involving its lead candidate PDS0101 in advanced HPV-associated cancers. The 56-patient trial led by Natio...
FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing molecularly-targeted cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Inf...
FLORHAM PARK, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...
After four straight sessions of declines, the shares of PDS Biotechnology (PDSB +3.0%) are trading higher on Thursday after the clinical-stage biotech company reported initial safety data for an experimental drug combination from a mid-stage study in head and neck cancer. The Phase 2 VERSATIL...
Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or signi...
PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level. For fur...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectiou...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...